Alzheimer’s Association International Conference 2023 (AAIC 2023)

Findings from the ACHIEVE* study suggest that older adults who are at increased risk for cognitive decline and dementia and who have hearing loss may benefit the most from hearing intervention within 3 years.

In the phase III TRAILBLAZER-ALZ 2 study, donanemab significantly slowed clinical progression in individuals with early symptomatic Alzheimer’s disease* (AD) with amyloid and tau pathologies, demonstrating an important replication of the phase II findings.